The prospective randomized trial evaluating the efficacy of the mitomycin C and cisplatin regimen (MP) versus standard first-line chemotherapy in patients with advanced BRCA1/2-associated ovarian cancer (NCT04747717). Voprosy onkologii, v. 68, n. 5, p. 628–638, 27 Oct.2022.